Image Description




Here you can find the latest articles about Cytokinetics, along with fact sheets describing the company, our clinical programs and background on our areas of disease focus – ALS, heart failure and SMA.

Date Title  
September 2017, Pharma Voice Patient-Centered Trials
August 22, 2017, The Pharma Letter 'Writing on the wall' suggests progress in ALS may be imminent, says Cytokinetics CEO
August 16, 2017, ALS Research Forum Cytokinetics CK-107 Muscles In at Phase 2
July 10, 2017, First World Pharma Spotlight On: Cytokinetics, Astellas muscling up on plans for troponin activators
March 23, 2017, SMA News Today Cytokinetics' CK-2127107 Improves Muscle Function in Mice with SMA, Study Shows
February 3, 2017, BioWorld $100M positions Cytokinetics well re Amgen with omecamtiv
February 2, 2017, BioCentury Cytokinetics strikes royalty deal for omecamtiv mecarbil
February 2, 2017, Xconomy Royalty Pharma Pays $90M to Cytokinetics for Heart Drug Royalties
February 2, 2017, BioPharma Dive Cytokinetics pulls in Royalty Pharma to secure $100M
February 2, 2017, First Word Pharma ViewPoints: Cytokinetics, Amgen have long believed omecamtiv mecarbil is a blockbuster in waiting - Royalty Pharma clearly agrees
December 12, 2016, ALS News Today Cytokinetics Presents New Data at 27th International Symposium on ALS/MND
December 5, 2016, Cardiovascular Business Oral heart failure medication proves safe, effective in phase 2 trial
October 13, 2016, Harvard Business School Adding Muscle to the Fight Against Disease
September 2, 2016, BioWorld Amgen to carry Cytokinetics HF drug into phase III
August 23, 2016, EP Vantage Interview – Cytokinetics muscles up in Lou Gehrig's disease
August 23, 2016, ALS News Today Cytokinetics Enrolls 700 ALS Patients in Phase 3 Study of Tirasemtiv
August 19, 2016, The Pink Sheet Cytokinetics Seeks ALS Success By Focusing On Lung Function
July 28, 2016, ALS News Today Cytokinetics and ALS Association Expand Efforts to Improve ALS Treatment and Care
July 28, 2016, BioWorld Expanded Astellas deal to advance Cytokinetics muscle biology in ALS
July 27, 2016, Endpoints Eyeing a potential market launch, Astellas orders up a $95M third course of Cytokinetics' pipeline
July 27, 2016, FierceBiotech Astellas boosts funding, involvement in updated Cytokinetics collab
July 27, 2016, KCBS SF Bay Area Major Funding For New Drugs To Help People Suffering From ALS
July 27, 2016, Xconomy Cytokinetics Gets $95M in First ALS Deal, Needs Results For More
July 5, 2016, COPD News Today Cytokinetics Begins Phase 2 Study of Therapy for COPD Patients




( FY )


( FY )


( FY )